| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Antoine Kimmoun | |
| Bruno Levy | |||
| Audrey Jacquot | |||
| Thomas Auchet | |||
| Caroline Fritz | |||
| Elsa Tahon | |||
| P2860 | cites work | Comparison of Dopamine and Norepinephrine in the Treatment of Shock | Q22250880 |
| Vasopressors for hypotensive shock | Q24186138 | ||
| The sympathetic nerve--an integrative interface between two supersystems: the brain and the immune system | Q28140631 | ||
| NOREPINEPHRINE: NOT TOO MUCH, TOO LONG. | Q33423986 | ||
| Outcome of patients with septic shock and high-dose vasopressor therapy | Q33580796 | ||
| The angiotensin II AT1 receptor-associated protein Arap1 is involved in sepsis-induced hypotension | Q33750365 | ||
| Plasma adrenomedullin is associated with short-term mortality and vasopressor requirement in patients admitted with sepsis. | Q33750991 | ||
| Alpha 1-adrenoceptors: function and phosphorylation | Q33844412 | ||
| Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells | Q33928022 | ||
| Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells | Q34191527 | ||
| The pathogenesis of vasodilatory shock | Q34350541 | ||
| Clinical review: interpretation of arterial pressure wave in shock states | Q34480809 | ||
| Vasopressin versus norepinephrine infusion in patients with septic shock. | Q34756330 | ||
| New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine/intracellular angiotensin II | Q35109349 | ||
| The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis* | Q35137091 | ||
| Renin: origin, secretion and synthesis | Q35209361 | ||
| Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock | Q35621102 | ||
| Postresuscitation disease after cardiac arrest: a sepsis-like syndrome? | Q35786349 | ||
| Systemic release of cytokines and heat shock proteins in porcine models of polytrauma and hemorrhage*. | Q36058029 | ||
| Use of inotropes and vasopressor agents in critically ill patients. | Q36147248 | ||
| Dexmedetomidine: a novel sedative-analgesic agent | Q36348758 | ||
| A Selective V(1A) Receptor Agonist, Selepressin, Is Superior to Arginine Vasopressin and to Norepinephrine in Ovine Septic Shock | Q36384718 | ||
| Use of methylene blue in sepsis: a systematic review | Q36649385 | ||
| Vasopressin: mechanisms of action on the vasculature in health and in septic shock | Q36667777 | ||
| Adrenomedullin binding improves catecholamine responsiveness and kidney function in resuscitated murine septic shock | Q36700440 | ||
| The tragedy of TRIUMPH for nitric oxide synthesis inhibition in cardiogenic shock: where do we go from here? | Q36978197 | ||
| Impact of vasopressin analogues on the gut mucosal microcirculation | Q37236203 | ||
| Methylene blue decreases ischemia-reperfusion (I/R)-induced spinal cord injury: an in vivo study in an I/R rabbit model. | Q50475318 | ||
| Clonidine and dexmedetomidine increase the pressor response to norepinephrine in experimental sepsis: a pilot study. | Q50694847 | ||
| Methylene blue increases myocardial function in septic shock | Q50759485 | ||
| Beneficial Effects of Norepinephrine Alone on Cardiovascular Function and Tissue Oxygenation in a Pig Model of Cardiogenic Shock. | Q53798642 | ||
| Myocardial and vascular adrenergic alterations in a rat model of endotoxin shock: reversal by an anti-tumor necrosis factor-alpha monoclonal antibody. | Q54569746 | ||
| Norepinephrine plus dobutamine versus epinephrine alone for management of septic shock: a randomised trial | Q57778873 | ||
| Serious adverse events associated with vasopressin and norepinephrine infusion in septic shock. | Q64917274 | ||
| Changes in α-adrenergic receptors in dog livers during endotoxic shock | Q67279440 | ||
| Effect of hydrocortisone on phenylephrine--mean arterial pressure dose-response relationship in septic shock | Q73028188 | ||
| Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study | Q73182846 | ||
| Reversal by vasopressin of intractable hypotension in the late phase of hemorrhagic shock | Q78017112 | ||
| Inappropriate sympathetic activation at onset of septic shock: a spectral analysis approach | Q78077522 | ||
| Blockade of multiple but not single cytokines abrogates downregulation of angiotensin II type-I receptors and anticipates septic shock | Q84902945 | ||
| Abstracts of the 42nd Critical Care Congress. January 19-23, 2013. San Juan, Puerto Rico | Q85616594 | ||
| Angiotensin-II: more than just another vasoconstrictor to treat septic shock-induced hypotension?* | Q87402641 | ||
| Selepressin in septic shock: sharpening the VASST effects of vasopressin?* | Q88087778 | ||
| Continuous terlipressin versus vasopressin infusion in septic shock (TERLIVAP): a randomized, controlled pilot study | Q37360357 | ||
| Effects of low doses of esmolol on cardiac and vascular function in experimental septic shock | Q37523087 | ||
| Methylene blue for the treatment of septic shock | Q37767426 | ||
| Vascular hyporesponsiveness to vasopressors in septic shock: from bench to bedside | Q37791460 | ||
| The cytokine responsive vascular smooth muscle cell enhancer of inducible nitric oxide synthase. Activation by nuclear factor-kappa B. | Q38288133 | ||
| Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock | Q38382864 | ||
| Effect of Early Vasopressin vs Norepinephrine on Kidney Failure in Patients With Septic Shock: The VANISH Randomized Clinical Trial | Q38389309 | ||
| Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial | Q38398337 | ||
| Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. | Q38433744 | ||
| Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial | Q38443276 | ||
| What's new in vasopressin? | Q38462941 | ||
| Methylene Blue: Magic Bullet for Vasoplegia? | Q38672163 | ||
| Angiotensin II in Refractory Septic Shock | Q38791618 | ||
| Association Between US Norepinephrine Shortage and Mortality Among Patients With Septic Shock | Q38891427 | ||
| Unlike arginine vasopressin, the selective V1a receptor agonist FE 202158 does not cause procoagulant effects by releasing von Willebrand factor. | Q39631236 | ||
| Heart rate reduction with esmolol is associated with improved arterial elastance in patients with septic shock: a prospective observational study. | Q39833414 | ||
| Non-Hemodynamic Effects of Catecholamines | Q40043868 | ||
| Vasopressin versus Norepinephrine in Patients with Vasoplegic Shock after Cardiac Surgery: The VANCS Randomized Controlled Trial | Q40420319 | ||
| Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock | Q40502831 | ||
| Clonidine Restores Pressor Responsiveness to Phenylephrine and Angiotensin II in Ovine Sepsis | Q41346510 | ||
| Effects of dexmedetomidine and esmolol on systemic hemodynamics and exogenous lactate clearance in early experimental septic shock. | Q41847224 | ||
| Corticosteroids suppress cyclooxygenase messenger RNA levels and prostanoid synthesis in cultured vascular cells | Q42513284 | ||
| Glucocorticoids modulate vascular reactivity in the rat. | Q42524486 | ||
| Dobutamine-norepinephrine, but not vasopressin, restores the ventriculoarterial matching in experimental cardiogenic shock | Q42849552 | ||
| beta2-Adrenergic receptor gene polymorphism is associated with mortality in septic shock | Q43256385 | ||
| Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial | Q43412778 | ||
| Comparison of equipressor doses of norepinephrine, epinephrine, and phenylephrine on septic myocardial dysfunction. | Q44202616 | ||
| Vasopressin compared with norepinephrine augments the decline of plasma cytokine levels in septic shock | Q44867475 | ||
| Relation between muscle Na+K+ ATPase activity and raised lactate concentrations in septic shock: a prospective study | Q45308330 | ||
| Hemodynamic variables related to outcome in septic shock | Q46562471 | ||
| Interaction of arginine vasopressin and angiotensin II on Ca2+ in vascular smooth muscle cells | Q46689927 | ||
| Cardiovascular response to dopamine and early prediction of outcome in septic shock: a prospective multiple-center study | Q46744325 | ||
| Decreased vasopressin responsiveness in vasodilatory septic shock-like conditions | Q46950029 | ||
| Safety of peripheral intravenous administration of vasoactive medication | Q47970105 | ||
| The neuropathology of septic shock. | Q48007037 | ||
| Mechanisms of vascular hyporesponsiveness in septic shock | Q48277227 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P921 | main subject | vasoconstrictor agents | Q3359124 |
| vasoplegia | Q3554941 | ||
| adrenal cortex hormone | Q38638276 | ||
| P304 | page(s) | 52 | |
| P577 | publication date | 2018-02-27 | |
| P1433 | published in | Critical Care | Q5186602 |
| P1476 | title | Vasoplegia treatments: the past, the present, and the future | |
| P478 | volume | 22 |
| Q92060027 | Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats |
| Q57816919 | Autonomic Nervous System Dysfunction in Pediatric Sepsis |
| Q54964321 | Blocking soluble guanylate cyclase could be the present and future of NO/cGMP inhibition for vasoplegia treatment. |
| Q64112965 | Cardiovascular determinants of resuscitation from sepsis and septic shock |
| Q97551221 | Good or bad: Application of RAAS inhibitors in COVID-19 patients with cardiovascular comorbidities |
| Q58100521 | Hemodynamic support in the early phase of septic shock: a review of challenges and unanswered questions |
| Q90599902 | Heterogeneity of Cardiovascular Response to Standardized Sepsis Resuscitation |
| Q90720520 | Ischemia/Reperfusion Injury Revisited: An Overview of the Latest Pharmacological Strategies |
| Q90101750 | Less is more: catecholamine-sparing strategies in septic shock |
| Q99576354 | New Agents in Development for Sepsis: Any Reason for Hope? |
| Q90070610 | Peroxynitrite decomposition catalyst reduces vasopressin requirement in ovine MRSA sepsis |
| Q64075378 | Role of nurses and nurse practitioners in the recognition, diagnosis, and management of neurogenic orthostatic hypotension: a narrative review |
| Q55245821 | The mechanism of action of the adrenomedullin-binding antibody adrecizumab. |
| Q90355869 | The renal vasodilatory effect of prostaglandins is ameliorated in isolated-perfused kidneys of endotoxemic mice |
| Q89530771 | Vasoplegic syndrome following cardiothoracic surgery-review of pathophysiology and update of treatment options |
| Q92865284 | Vasopressin and its analogues in shock states: a review |
Search more.